FDA product approval
approved product. Egrifta WR, for its labeled HIV-associated indication.
GH secretagogue · compound · checked 2026-10-09
Tesamorelin math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 5 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.
Last checked Oct 9, 2026 by PepBear. Not medical advice.
U-100 math for listed Tesamorelin sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.
| Listed vial | 1 mL liquid | 2 mL liquid | 3 mL liquid |
|---|---|---|---|
| 5 mg | 50 | 25 | 16.7 |
| 10 mg | 100 | 50 | 33.3 |
Approved-product evidence applies to that use only. Putting the tesamorelin name on a research vial does not extend Egrifta’s approval to general body-composition wellness. The catalog keeps those identities separate.
Growth-hormone-releasing-hormone analogue.
FDA product approval
approved product. Egrifta WR, for its labeled HIV-associated indication.
Compounding
not established. Compounded products do not carry FDA product approval; legal eligibility is not established here.
Research
product specific. Adults with HIV-associated lipodystrophy and excess abdominal fat; not general weight loss.
Sport
prohibited. WADA S2 lists this GHRH analogue.
Falutz et al. (PMID 20554713) and the Egrifta label describe belly-fat changes in the studied HIV group on the approved product. Injection-site reactions and blood-sugar changes appear in label materials. Those facts do not create a general fat-loss use. They do not validate a 5 mg research vial. A Friday log that copies the Egrifta carton onto a research listing is mixing two products that this card keeps apart.
We mark the cited papers as A. That is our label for how strong those papers are. It does not say the compound works.
0.18333333333333332 hours. About eleven minutes for the labeled Egrifta WR formulation in healthy subjects; formulations differ.
Egrifta has carton storage. Research vials have whatever the seller printed. This chart uses 5 mg and 10 mg listings from the vendor file only.
People using PepBear often log: Existing clinician-directed records, symptoms and dated health measurements. Record missing data; trends do not demonstrate causation.
The cited approval is for Egrifta and HIV-related lipodystrophy. This page does not extend that use.
People also hold research-market vials and ask for unit math. The calculator never copies the Egrifta schedule.
Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.
A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.
A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.